$ADMA Investor News: ADMA Biologics Faces Securities Fraud Investigation after Culper Research Revelation Leads to 29% Stock Drop – BFA Law Notifies Investors to Act

Core Viewpoint - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws, specifically related to allegations of channel stuffing to inflate revenue figures [1][2]. Company Overview - ADMA Biologics is a biopharmaceutical company that focuses on manufacturing and developing specialty biologics, with its flagship product being ASCENIV, a liquid immune globulin solution for treating Primary Humoral Immunodeficiency [2]. Allegations and Investigation - The investigation by Bleichmar Fonti & Auld LLP is based on claims that ADMA Biologics reported a 20% revenue growth in 2025, which may have been artificially inflated through a channel stuffing scheme [2]. - Culper Research published a report indicating that ADMA Biologics allegedly induced a distributor to stock excess ASCENIV by offering rebates and extended payment terms, allowing the company to report growth that did not actually occur [3]. Financial Impact - The alleged channel stuffing scheme, if true, would have resulted in a revenue decline of 3% for ADMA Biologics in 2025, contrasting sharply with the reported 20% growth [3]. - Following the publication of the report, ADMA Biologics' stock price fell by $3.96 per share, or 29%, from $13.59 on March 23, 2026, to $9.63 on March 25, 2026 [4].